- Home
- FOA vs PBYI Comparison
FOA vs PBYI Comparison
Compare FOA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- PBYI
- Stock Information
- Founded
- FOA 2013
- PBYI 2010
- Country
- FOA United States
- PBYI United States
- Employees
- FOA N/A
- PBYI N/A
- Industry
- FOA Finance Companies
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- PBYI Health Care
- Exchange
- FOA Nasdaq
- PBYI Nasdaq
- Market Cap
- FOA 240.8M
- PBYI 153.2M
- IPO Year
- FOA N/A
- PBYI N/A
- Fundamental
- Price
- FOA $25.24
- PBYI $2.80
- Analyst Decision
- FOA Hold
- PBYI Strong Buy
- Analyst Count
- FOA 1
- PBYI 1
- Target Price
- FOA $24.00
- PBYI $7.00
- AVG Volume (30 Days)
- FOA 142.7K
- PBYI 402.6K
- Earning Date
- FOA 11-06-2024
- PBYI 11-07-2024
- Dividend Yield
- FOA N/A
- PBYI N/A
- EPS Growth
- FOA N/A
- PBYI 492.79
- EPS
- FOA 10.89
- PBYI 0.47
- Revenue
- FOA $719,526,000.00
- PBYI $243,569,000.00
- Revenue This Year
- FOA N/A
- PBYI N/A
- Revenue Next Year
- FOA N/A
- PBYI N/A
- P/E Ratio
- FOA $2.37
- PBYI $5.91
- Revenue Growth
- FOA 3011.46
- PBYI 6.30
- 52 Week Low
- FOA $4.10
- PBYI $2.23
- 52 Week High
- FOA $28.50
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- FOA 57.61
- PBYI 46.19
- Support Level
- FOA $23.46
- PBYI $2.72
- Resistance Level
- FOA $28.50
- PBYI $3.12
- Average True Range (ATR)
- FOA 2.70
- PBYI 0.19
- MACD
- FOA -0.01
- PBYI -0.04
- Stochastic Oscillator
- FOA 54.06
- PBYI 20.48
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to an range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.